Eli Lilly

Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values—excellence, 
integrity, and respect for people—that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities 
through philanthropy and volunteerism.
Company Growth (employees)
Type
Public
HQ
Indianapolis, US
Founded
1876
Size (employees)
41,975 (est)
Website
lilly.com
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US

Key People at Eli Lilly

John Lechleiter

John Lechleiter

Chairman, President, and CEO
David Ricks

David Ricks

President and Chief Executive Officer
Jan Lundberg

Jan Lundberg

Executive Vice President
Alfonso Zulueta

Alfonso Zulueta

Senior Vice President and President
Barton Peterson

Barton Peterson

Senior Vice President, Corporate Affairs and Communications
Derica Rice

Derica Rice

Executive Vice President, Global Services, and Chief Financial Officer
Jeffrey Simmons

Jeffrey Simmons

Senior Vice President
Melissa Barnes

Melissa Barnes

Senior Vice President
Enrique Conterno

Enrique Conterno

Senior Vice President
Maria Crowe

Maria Crowe

President, Manufacturing Operations
Michael Harrington

Michael Harrington

Senior Vice President and General Counsel
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Susan Mahony

Susan Mahony

Senior Vice President and President
Fionnuala Walsh

Fionnuala Walsh

Senior Vice President

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 2 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Toronto, CA
3650 Danforth Ave
Windlesham, GB
Erl Wood Manor Sunninghill Road
Melrose Park, AU
112 Wharf Rd
Wien, AT
8 10 Kölblgasse
Chuo Ward, JP
Sannomiya Plaza Building 7 1 5 Isogami Dori Chuo Ku, Kobe

Eli Lilly Data and Metrics

Eli Lilly Financial Metrics

Eli Lilly's revenue was reported to be $21.2 b in FY, 2016 which is a 6% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

21.2 b

Revenue growth (FY, 2015 - FY, 2016), %

6%

Gross profit (FY, 2016)

15.6 b

Gross profit margin (FY, 2016), %

73%

Net income (FY, 2016)

2.7 b

Market capitalization (26-May-2017)

82.4 b

Closing share price (26-May-2017)

78.3

Cash (31-Dec-2016)

4.6 b

EV

86.2 b
Eli Lilly's current market capitalization is $82.4 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1 b19.6 b20 b21.2 b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b

Gross profit Margin, %

79%75%75%73%

Pre tax profit

5.9 b3 b2.8 b3.4 b

Net Income

4.7 b2.4 b2.4 b2.7 b
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m

Inventories

2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b

PP&E

8 b8 b8.1 b8.3 b

Goodwill

1.8 b4 b4 b

Total Assets

35.2 b37.2 b35.6 b38.8 b

Accounts Payable

1.1 b1.1 b1.3 b1.3 b

Dividends Payable

523.5 m530.3 m539 m548.1 m

Total Debt

4.2 b5.4 b8 b8.4 b

Current Liabilities

8.9 b11.2 b8.2 b11 b

Common Stock

698.5 m694.6 m691.3 m

Additional Paid-in Capital

5.1 b5.3 b5.6 b5.6 b

Retained Earnings

17 b16.5 b16 b16 b

Total Equity

17.6 b15.4 b14.6 b14.1 b

Debt to Equity Ratio

0.2 x0.3 x0.5 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x0.2 x

Financial Leverage

2 x2.4 x2.4 x2.8 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)

Short-term Borrowings

2.7 b(2.7 b)1.3 b

Long-term Borrowings

(10.5 m)(1 b)(2 b)(200 k)

Dividends Paid

(2.1 b)(2.1 b)(2.1 b)(2.2 b)

Cash From Financing Activities

(3.8 b)(75.1 m)(2.9 b)(559.8 m)
Numbers are in $, USDY, 2016

EV/CFO

17.8 x

Revenue/Employee

511.3 k

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.8 x

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Projects in R&D Pipeline

57576566

Phase III Trials

871719

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.4 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.5 b

Eli Lilly Market Value History

Eli Lilly Median Salaries

Source: 117 public H-1B filings from Eli Lilly

Eli Lilly Online and Social Media Presence

Eli Lilly News and Updates

Eli Lilly Company Life and Culture

You may also be interested in